Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies. Chimerix is developing CMX157 for the treatment of HIV and HBV infections, including those caused by multi-drug resistant viruses. A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.
Chimerix has completed a Phase 2 randomized, double-blind, placebo-controlled, dose-escalation multi-center trial evaluating the safety, tolerability and ability of CMX001 to prevent or control CMV disease in 230 seropositive allogeneic cell transplant recipients. Read More
Chimerix has amassed an unusual breadth of assets with considerable potential in antiviral innovation, including our Lipid-Antiviral-Conjugate Technology and the Chimerix Chemical Library. The combination of our team’s internal antiviral product expertise with a number of internally-generated leads against several important viruses allows us the flexibility to pursue out-licensing or co-development partners for our emergent antiviral medicines. Read More